Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Innovus Pharmaceuticals, Inc. Market Cap
The Innovus Pharmaceuticals, Inc. (INNV) share price is expected to increase by 21.72% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered INNV. Price targets range from $6 at the low end to $7 at the high end. The current analyst consensus for INNV is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedINNV 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Innovus Pharmaceuticals, Inc. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on INNV. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of INNV.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Lisa Gill JP Morgan | Neutral | $6 | Maintains | Mar 13, 2024 |
| Jamie Perse Goldman Sachs | Neutral | $7 | Maintains | Feb 8, 2024 |
| Jamie Perse Goldman Sachs | Neutral | $9 | Maintains | Feb 15, 2023 |
| Lisa Gill JP Morgan | Neutral | $8 | Maintains | Feb 8, 2023 |
| Jamie Perse Goldman Sachs | Neutral | $8 | Maintains | Nov 23, 2022 |
| Jason Cassorla Citigroup | Neutral | $8 | Maintains | Nov 16, 2022 |
| Sarah James Barclays | Equal-Weight | $5 | Maintains | Sep 15, 2022 |
| Vikram Kesavabhotla Baird | Neutral | $5 | Downgrade | May 16, 2022 |
| Jeff Garro Piper Sandler | Underweight | $3.9 | Maintains | May 11, 2022 |
| Jeff Garro Piper Sandler | Underweight | $5 | Downgrade | Apr 20, 2022 |
| Jamie Perse Goldman Sachs | Neutral | $4 | Downgrade | Dec 28, 2021 |
| Sarah James Barclays | Equal-Weight | $6.5 | Downgrade | Dec 27, 2021 |
JP Morgan | Neutral | Initiates | Dec 17, 2021 | |
Citigroup | Neutral | Downgrade | Sep 29, 2021 | |
William Blair | Market Perform | Downgrade | Sep 22, 2021 | |
Cowen & Co. | Market Perform | Initiates | Sep 10, 2021 | |
| Steve Valiquette Barclays | Overweight | $19 | Upgrade | Aug 12, 2021 |
Baird | Outperform | Initiates | May 28, 2021 | |
William Blair | Outperform | Initiates | Mar 29, 2021 | |
Barclays | Equal-Weight | Initiates | Mar 29, 2021 |
When did it IPO
2020
Staff Count
2,350
Country
United States
Sector/Industry
Healthcare/Medical Care Facilities
CEO
Mr. Patrick Blair
Market Cap
$724.9M
In 2023, INNV generated $688.1M in revenue, which was a decrease of -1.51% from the previous year. This can be seen as a signal that INNV's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 16 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - InnovAge Holding Corp. (Nasdaq: INNV) is partnering in a national study aimed at preventing falls among seniors, potentially enhancing its service offerings in elderly care.
Why It Matters - InnovAge's partnership in a national study on fall prevention may enhance its reputation, potentially leading to increased funding, growth opportunities, and improved patient outcomes, positively impacting stock performance.
Mon, 16 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - InnovAge Holding Corp. corrected Dr. Ann Wells' title to Chief Quality and Population Health Officer in a recent release.
Why It Matters - The correction of Dr. Ann Wells' title may reflect changes in leadership or strategy at InnovAge, potentially impacting the company's operational focus and investor confidence.
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - InnovAge Holding Corp. (NASDAQ: INNV) will host its Q4 2024 earnings conference call on September 10, 2024, at 5:00 PM ET, featuring key executives and analysts from major firms.
Why It Matters - The Q4 2024 earnings call for InnovAge Holding Corp. will provide critical insights into the company's financial performance and future outlook, influencing stock valuations and investor sentiment.
Tue, 10 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - InnovAge Holding Corp. (Nasdaq: INNV) reported its fiscal Q4 and full-year financial results for the period ending June 30, 2024, focusing on healthcare programs for frail, dual-eligible seniors.
Why It Matters - InnovAge's financial results indicate its performance and growth potential in the healthcare sector for seniors, impacting stock valuation and investor confidence in its business model.
Tue, 10 Sep 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - InnovAge Holding Corp. (INNV) reported a quarterly loss of $0.01 per share, better than the expected loss of $0.02, and an improvement from a loss of $0.09 per share a year earlier.
Why It Matters - InnovAge's smaller-than-expected loss suggests improving financial performance, potentially boosting investor confidence and impacting stock valuation positively.
Thu, 22 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - InnovAge corrected its staff count from seven to 20 in a release dated August 16, 2024. The update pertains to data from four years ago.
Why It Matters - The correction in staff count may indicate a more substantial operational scale for InnovAge, potentially impacting valuation and investor confidence in growth prospects.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
